Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366757 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL29613402 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL30977677 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL12537019 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL29352409 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL29907974 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL118370 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL1486216 | 0.92 | MDM4 (0.61) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL29235897 | 0.88 | TLR2 (0.54) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL29373684 | 0.87 | MDM4 (0.51) | MDM4TP53CASP3SLC17A5MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723699-B1 | ADMINISTERING AS CHOLINERGIC AGENT TO TREAT NERVOUS SYSTEM DISORDERS | CEPHALON, INC. | 2004-04-20 | — | — | US | disclosed |
| US-6693076-B1 | ENHANCING SURVIVAL OF NEURONAL CELLS AT RISK OF DYING DUE TO INJURY OR EPILEPSY | CEPHALON, INC. | 2004-02-17 | — | — | US | disclosed |
| US-6310040-B1 | FOR PROMOTING THE SURVIVAL OF PHOTORECEPTORS IN A MAMMAL | CEPHALON, INC. | 2001-10-30 | — | — | US | disclosed |
| US-5776897-A | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5703045-A | NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5652214-A | ENHANCING SURVIVAL OF NEURONAL CELLS IN HEAD AND SPINAL CORD AFTER INJURY, ALSO TREATMENT OF AGING, ALZHEIMER*S, STROKE, EPILEPSY | CEPHALON, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0604605-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0670729-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |